Coadministration of flu and COVID-19 vaccines is safe and effective, according to findings published recently in JAMA Network Open, and Moderna report a strong immune response to its experimental vaccine that would combine flu and COVID-19 vaccination into a single shot.
Patterns in COVID-19 vaccinations remain largely divided along political party lines, according to one report.
It differs from the Pfizer and Moderna vaccine. Instead of using mRNA, the Novavax vaccines consists of proteins found in the spikes of the COVID-19 vaccine combined with an adjuvant made from the bark of a tree that grows in Chile.
In a 10-year study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.
Respiratory syncytial virus (RSV) can be deadly for the very young and the old and frail. GSK's vaccine will be marketed under the brand name Arexvy and Pfizer's under the name Abrysvo.
The purpose of the federal vaccine safety reporting system often is misunderstood, and its data can be easily used to spread false information about vaccination. A new report from the Annenberg Public Policy Center at the University of Pennsylvania looks at how it was manipulated to raise doubts about COVID-19 vaccines and suggests remedies.
Seasonal influenza kills hundreds of thousands of people every year due to a constantly changing virus and highly inefficient vaccine production. A universal flu vaccine could deal with the first problem, and mRNA technology with the second.
In his closing thoughts, Dr Lewis offers considerations for key decision-makers regarding new vaccines entering the marketplace.
Dr Lewis provides insight into general unmet needs surrounding vaccines.
Vaccine accessibility has been limited for patients impacted by health disparities and social determinants of health (SDoH).
Researchers have spent a century trying to develop a vaccine against malaria, one of the world’s biggest killers. The first shot to be approved, two years ago, is 30% effective. A new one, in the works for three decades, has a reported 77% efficacy and a licensee with the capacity to produce 200 million doses a year.
Dr Lewis discusses his organization’s leveraging of EMR to track immunization status of patients.
The COVID-19 pandemic has influenced patient perception regarding many aspects of vaccination safety and efficacy.
The federal government is hoping that newly simplified vaccination guidelines will lead more Americans to get vaccinated against COVID-19. In other pandemic news, HHS announced plans to keep vaccines and treatments free for the uninsured, and an appellate court sided with the Biden administration's disputed vaccination requirement for federal contractors.
James Lewis, PharmD, FIDSA, opens a discussion regarding the current and anticipated landscape surrounding vaccination.
Despite decades of research, no available vaccine targets respiratory syncytial virus (RSV), a disease that causes hundreds of thousands of deaths worldwide among young children and older adults. Interim results of two late-stage trials of Pfizer’sRSV prefusion F vaccine suggest the vaccine is efficacious, although the low RSV infection rates during the high COVID-19 pandemic years limited some of the findings.
Vaccine hesitancy has many causes. A new study examined how the nocebo effect — beliefs that negative side effects will occur — may be a factor in people’s response to COVID-19 vaccination and could play into hesitancy dynamics.
Although it’s not likely to pass, at least not this year, opponents say the proposal is already accelerating the spread of false claims and sowing distrust of physicians.
Global polio eradication efforts have reduced cases of the deadly disease by 99.99% in 35 years. Yet it continues to circulate in over 30 countries. The most dangerous form is endemic in Pakistan and Afghanistan, where it seeds outbreaks elsewhere.
Increasing numbers of adults are getting vaccinated at pharmacies. But many states limit pharmacists’ ability to immunize children. Pharmacist participation in the federal Vaccines for Children program is even more restricted.
Research stalled for decades after deaths in a 1960s trial. Now Pfizer and other companies are reporting results for a vaccine against respiratory syncytial virus infections.
Vaccination rates are struck below levels needed to eradicate measles. Members of three generations of a family with expertise in vaccines propose a novel approach to improving measles vaccination rates. It could include a whistle.
Pfizer could soon be the first to offer an RSV vaccine to adults ages 60 and older if the vaccine is fully approved by the Food Drug and Administration and the Centers for Disease Control and Prevention.
Program reached the Marshallese workers who have moved from the island nation in the central Pacific Ocean to work in the poultry and meatpacking industry in northwest Arkansas.
It took less than a year to develop the first COVID-19 vaccine, but an epidemic preparation group has said even more speed could be added and proposed setting 100 days as a goal for the development of future vaccines,
